tiprankstipranks
Advertisement
Advertisement
Pyxis Oncology price target lowered to $8 from $9 at Stifel
PremiumThe FlyPyxis Oncology price target lowered to $8 from $9 at Stifel
2M ago
Pyxis Oncology Reports Q4 Results, Advances MICVO Program
Premium
Company Announcements
Pyxis Oncology Reports Q4 Results, Advances MICVO Program
2M ago
PYXS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
PYXS Earnings this Week: How Will it Perform?
2M ago
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
PremiumRatingsMaintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
6M ago
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
Premium
The Fly
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
6M ago
Pyxis Oncology Reports Strong MICVO Data and Financing
Premium
Company Announcements
Pyxis Oncology Reports Strong MICVO Data and Financing
6M ago
Pyxis Oncology price target raised to $8 from $5 at Stephens
PremiumThe FlyPyxis Oncology price target raised to $8 from $5 at Stephens
6M ago
Pyxis Oncology Reports Increased Losses Amid Development Focus
Premium
Company Announcements
Pyxis Oncology Reports Increased Losses Amid Development Focus
7M ago
Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
Premium
Ratings
Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100